Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance aripiprazole in pediatric Tourette's disorder
2018-002270-48Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Tourette syndrome (TS) comparing Aripiprazole with Placebo (2 arms). Primary endpoint: Time from randomization to relapse. Started Dec 2018; status: terminated.
02
Drugs
aripiprazole
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2018-002270-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002270-48.